Searchable abstracts of presentations at key conferences in endocrinology

ea0021p354 | Steroids | SFEBES2009

Low testosterone and androgen receptor insensitivity results in decreased AMP-activated protein kinase activity (AMPK) in the liver in the testicular feminised (Tfm) mouse

Igreja Susana , Nettleship Joanne E , Jones Richard D , Channer Kevin S , Jones T Hugh , Korbonits Marta

There are controversial data on the beneficial/detrimental effects on the cardiovascular as well as on the metabolic system by the sex hormone testosterone. Recent data support the hypothesis that low levels of androgens are associated with adverse cardiovascular risk factors including an atherogenic lipid profile, obesity, insulin resistance and hypertension. AMPK is a sensor of energy balance at both the cellular and whole-body level. Once activated by low energy status, it ...

ea0014oc6.2 | Cardiovascular endocrinology | ECE2007

Testosterone replacement attenuates fatty streak formation and improves the HDLC profile in the Tfm mouse: an effect which is independent of the classical androgen receptor

Nettleship Joanne E , Jones Richard D , Channer Kevin S , Jones Hugh T

Research indicates that low testosterone is associated with CAD in men. Evidence suggests that men with hypotestosteronemia and concomitant CAD may benefit from physiological testosterone replacement therapy (PTRT). The mechanism by which testosterone produces these cardio-protective effects and the role of the androgen receptor remains largely unknown. The aim of this study was to determine whether testosterone modulates atheroma formation via its classical signalling pathway...

ea0014oc7.7 | Reproductive endocrinology I | ECE2007

Use of atorvastatin, but not simvastatin in men with Type 2 diabetes is associated with lower total testosterone levels with no effect on bioavailable or free testosterone

Stanworth Roger D , Kapoor Dheeraj , Channer Kevin S , Jones T Hugh

There is a high prevalence of low testosterone levels in men with type 2 diabetes (DM2) and low testosterone predates the onset of DM2. Testosterone replacement therapy for hypogonadal men with DM2 improves insulin sensitivity and glycaemic control as well as reducing central obesity. This may lead to an increase in biochemical assessment of hypogonadism in men with DM2. Androgens and other steroid hormones are produced from cholesterol and it has been postulated that treatmen...

ea0014p628 | (1) | ECE2007

Testosterone levels correlate positively with HDL cholesterol levels in men with Type 2 diabetes

D Stanworth Roger , Kapoor Dheeraj , Channer Kevin S , Hugh Jones T

Low testosterone levels are a common finding in men with coronary artery disease and Type 2 diabetes and predict the future development of the metabolic syndrome and Type 2 diabetes in healthy men. Testosterone replacement therapy has been shown to improve insulin sensitivity and glycaemic control in men with diabetes and improves numerous other cardiovascular risk factors. Interest in testosterone as a potential treatment for cardiovascular disease continues to grow. Low HDL ...

ea0013oc37 | British Thyroid Association Award | SFEBES2007

Testosterone replacement attenuates fatty streak formation and improves the HDLC profile in the Tfm mouse: an effect which is independent of the classical androgen receptor

Nettleship Joanne E , Jones Richard D , Channer Kevin S , Jones Hugh T

Research indicates that low testosterone is associated with CAD in men. Evidence suggests that men with hypotestosteronemia and concomitant CAD may benefit from physiological testosterone replacement therapy (PTRT). The mechanism by which testosterone produces these cardio-protective effects and the role of the androgen receptor remains largely unknown. The aim of this study was to determine whether testosterone modulates atheroma formation via its classical signalling ...